Article
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Thoracic cancer - 1 Nov 2016
Zhu Yanzhe, Du Yingying, Liu Hu, Ma Tai, Shen Yuanyuan, Pan Yueyin
Abstract excerpt
BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.